Compare AbbVie Inc (ABBV) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Zeta Global Holdings Corp — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Zeta Global Holdings Corp trades at $21.56 (market cap $5.45B). The key difference: AbbVie Inc is far larger — about 82.6× Zeta Global Holdings Corp's market cap, and AbbVie Inc pays a 2.72% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| ABBV | ZETA | |
|---|---|---|
Market Cap | $449.91B | $5.45B |
Sector | Health | Technology |
52-Week High | $261.07 | $25.24 |
52-Week Low | $184.85 | $14.00 |
Enterprise Value | $513.38B | $5.36B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
ZETA trades at $21.82, up 5.46% over the past 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $27.50. Recent earnings beats and a strategic AI partnership with Palantir highlight strong operational momentum, though negative net income and cash flow remain concerns. The stock shows robust revenue growth and high gross margins, supported by positive media coverage and institutional interest.
The outlook for ZETA is cautiously optimistic, driven by AI integration and consistent earnings outperformance. Key risks include persistent unprofitability and competitive pressures in the marketing technology sector. Investors should weigh the high valuation multiples against growth potential, with analyst sentiment strongly favoring buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
